secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001704292-25-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q3 revenue up 14% to $116.1M; loss narrows; revises FY2025 guidance to at least $460M
--------------------------------------------------------------------------------

- Product revenue $115.4M (+13% YoY); VYVGART $27.7M, ZEJULA $42.4M, NUZYRA $15.4M.
- Operating loss improved 28% YoY to $48.8M GAAP; adjusted operating loss $28.0M (-42% YoY).
- Net loss $36.0M ($0.33/ADS) vs $41.7M ($0.42/ADS) in Q3 2024.
- Global registrational study for zoci (DLL3 ADC) initiated; Phase 1 data showed 68% ORR at 1.6 mg/kg in 2L+ ES-SCLC.
- Cash $817.2M; FY2025 revenue guidance revised to at least $460M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000170429225000023/0001704292-25-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000170429225000023/zlab-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001704292-25-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer